Owlstone Medical, the UK-based developer of “breath biomarkers” for various medical diagnostics purposes, has won a contract from the US Department of Defense that will put a lightweight, portable version of its technology on the battlefield.
Minute Insight: Owlstone Medical’s 'Breath Biopsy' Tech Adopted By US Military
The company will create a handheld version of its FAIMS technology, to be used in rapid testing for transmissible illnesses in combat scenarios.
More from Minute Insights
• By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
• By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
• By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
• By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
• By
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
• By
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.